Lichen Planus Market
Report ID: SQMIG35I2572
Report ID: SQMIG35I2572
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2572 |
Region:
Global |
Published Date: March, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Lichen Planus Market size was valued at USD 200.10 Million in 2024 and is poised to grow from USD 215.71 Million in 2025 to USD 393.38 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
The primary driver of the lichen planus market is the rising prevalence of autoimmune and inflammatory disorders combined with improved diagnostic awareness, which together expand patient identification and treatment demand. Lichen planus is a long-term illness that affects the skin, oral cavity, scalp, and nails. With its impact on quality of life, and minimal approved treatments, there are many concerns with lichen planus. Over time the market evolved from off-label corticosteroid reliance to targeted biologics and topical formulations evaluated in clinical trials, and emerging JAK inhibitors pursued by dermatology firms.
Building on rising diagnosis rates, the key trend driving the global lichen planus sector growth is intensified clinical development and commercialization of targeted therapies because pharmaceutical investment follows clear unmet need signals, resulting in broader pipelines and licensing deals. As companies prioritize JAK inhibitors, clinical trial activity increases, which in turn attracts specialist networks and reimbursement discussions; for example, a firm’s phase II positive data for a topical JAK candidate prompted partnerships with dermatology clinics to run real-world effectiveness pilots. Consequently, further expanded trial evidence and improved payer models create opportunities for oral medicine integration, teledermatology triage, and market entry in emerging regions.
How is AI Transforming the Lichen Planus Treatment Market?
AI is reshaping the lichen planus market by improving diagnosis, patient selection, drug discovery, and clinical research. Image based deep learning and computational pathology enable more objective identification of oral and cutaneous variants and better risk assessment. Automated histology review and biomarker detection powered by artificial intelligence significantly accelerate the pace of translational research and allow for more targeted approaches to therapy. In an industry characterized by an abundance of unmet demand, changing therapeutic modalities, and other circumstances affecting the delivery of care, these technologies will help clinicians and developers cut down on diagnostic delays and allocate resources to patients with a higher probability of benefiting from the diagnosis.
In December 2025, Aiforia released Aiforia 7.0 which expanded its foundation AI engine for pathology image analysis. This innovation helps the lichen planus market by accelerating histology interpretation and improving patient stratification for trials, thereby supporting more efficient development and smarter clinical decision making.
Market snapshot - (2026-2033)
Global Market Size
USD 200.1 Million
Largest Segment
Cutaneous Lichen Planus
Fastest Growth
Oral Lichen Planus
Growth Rate
7.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global lichen planus market is segmented by disease type, treatment type, route of administration, end user and region. Based on disease type, the market is segmented into cutaneous lichen planus, oral lichen planus, genital lichen planus and lichen planus pigmentosa. Based on treatment type, the market is segmented into topical therapies, systemic therapies, phototherapy and alternative treatments. Based on route of administration, the market is segmented into topical, oral, intravenous and intradermal. Based on end user, the market is segmented into hospital, dermatology clinic and homecare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global lichen planus market growth, oral lichen planus segment dominates because its chronic mucosal involvement generates sustained diagnostic and therapeutic demand that prioritizes specialized care pathways. Having chronic pain while swallowing or talking causes patients to see their doctors regularly and receive multiple treatments for these issues as well as create a need for new formulations that are specifically developed to treat them, along with the development of new and different How-To guides for health care providers to use when managing these problems. This prolonged treatment horizon and the complexity of monitoring disease activity cause higher utilization of multidisciplinary services and stimulate R&D focus, securing its leadership in the market.
However, cutaneous lichen planus is the most rapidly expanding area owing to growing demand for topical and phototherapy options and increased dermatologist awareness. Topical agents of the targeted variety and phototherapy have developed quickly too with clinicians becoming increasingly capable of recognizing different types of presentations which makes increased use of these therapies allow for new product development and also creates new opportunities for outpatient treatment.
Topical therapies segment dominates because topical application delivers targeted symptom control with lower systemic risk, making it the preferred first line approach for many manifestations of lichen planus. The ease of use for administration and compatibility for long-term use has created an inclination, both for the physician and the patient to prescribe medications routinely, which drives consistent demand. The practical therapeutic profile also supports an extensive range of products from corticosteroids to cutting-edge topical immunomodulators and is the basis for ongoing investments in improving formulations.
However, systemic therapies are emerging as the fastest expanding area driven by unmet needs in severe or refractory cases and growing interest in targeted immunomodulators. Novel oral agents and biologics in development, along with clinician readiness to escalate treatment for durable remission, are accelerating demand and refocusing pipeline priorities toward systemic solutions.
To get detailed segments analysis, Request a Free Sample Report
As per the global lichen planus market share, North America benefits from a combination of advanced clinical infrastructure, strong research ecosystems, and concentrated investments in dermatology that reinforce its leadership in the Lichen Planus market. Regulatory policies that promote the rapid progression of clinical development, and create access channels to allow for timely commercial introduction as well as incorporation of new products into clinical practice, will assist in creating supportive environment for new product introductions and incorporation into clinical practice. A well-established network of specialist clinicians along with academic institutions generating clinical evidence and productive multidisciplinary care models also provide support for the potential incorporation of new therapies and diagnostics into clinical practice. Access and payment mechanisms through established reimbursement policies and engagement with payers enable patient access and commercial viability, whilst active advocacy from the patient community/interest groups and professional organizations create awareness and assist in guideline development.
Lichen planus market in United States reflects a mature clinical and commercial ecosystem characterized by specialized dermatology centers, clinical research activity, and integrated care pathways that support adoption of new therapies. Payers’ engagement and established distribution systems together allow easier access for patients; however, academic institutions can create new evidence through research and development to enhance drug development. Active professional societies and patient advocacy groups help to promote awareness of drugs and aid in the establishment of clinical guidelines; therefore, all these factors work to provide a long-term market presence and new developments for therapies.
Lichen planus market in Canada benefits from a collaborative healthcare landscape where regional specialist networks contribute to clinical knowledge and patient care pathways. Emphasis on integrated dermatology services and structured referral systems supports diagnosis and management, while public and private payer frameworks shape access considerations. In partnership with the industry, clinical centres, and others can work together to enhance local support programs and awareness campaigns related to health care. Patient advocacy and medical education among clinicians strengthen practice standards and therapeutic adoption.
Based on global lichen planus regional forecast, expansion in Europe of the industry is driven by an increasingly coordinated clinical research environment, growing awareness among clinicians and patients, and strengthening healthcare delivery models across major markets. However, access dynamics are influenced by national payer frameworks and evolving reimbursement practices. Investment in specialist dermatology services and multidisciplinary care pathways provide the opportunity to increase accuracy of diagnosis and improve management of patients with dermatologic conditions. In addition, growing involvement of patient advocacy groups and professional societies supports guideline development and clinician education. By forming strategic partnerships between industry and regional healthcare networks there is an opportunity to develop tailored commercialization strategies to meet the varying needs of the markets in the region; thus, the region is quickly becoming a leader in the therapeutic development and clinical adoption of Lichen Planus.
Lichen planus market in Germany exemplifies a leading role driven by concentrated clinical expertise, specialist networks, and research collaboration between academic centers. Pathways for evidence generation and clinical evaluation enable the advancement of therapies. The integration of new treatment modalities will be facilitated by having a more organized healthcare delivery system and clear reimbursement methods. Active participation from professional societies in the education of clinicians supports the provision of care according to guidelines and promotes management criteria on a national basis.
Lichen planus market in United Kingdom is characterized by proactive clinical adoption, strong primary care engagement in dermatology pathways, and investment in specialist services. The presence of a flexible regulatory and reimbursement framework enables clinical assessment and ultimately the introduction of new treatments into clinical practice. The combined efforts of the patient advocacy community, as well as the professional society organizations, help to promote awareness among physicians, enhance their knowledge of new treatments, and facilitate guidelines on how to implement new therapies across all practice settings.
Lichen planus market in France is an emerging landscape shaped by growing clinical focus on dermatology care, increasing coordination between hospitals and academic centers, and evolving treatment pathways. Clinicians who are educated about their practice will be able to better diagnose patients and manage their symptoms with more effective management techniques. Partnership among the healthcare industry and practice provides early opportunities for continued clinical education and developing a greater awareness of available clinical services. Patient organizations and professional societies help disseminate best practices and promote standardized care approaches across national healthcare settings.
As per the global lichen planus regional outlook, Asia Pacific is strengthening its position in the industry through strategic investments in clinical research capacity, expansion of specialist care infrastructure, and increased collaboration between regional academic centers and global industry partners. A growing focus on developing standardised pathways and diagnosis of illnesses is improving the diagnosis and treatment of illnesses in different healthcare systems. Through regulatory involvement and local clinical programmes, there is an increase in the generation of regional evidence to support new market entry strategies that fit the region. There are increasing numbers of clinician education initiatives and patient awareness campaigns supported by market-specific commercialisation strategies to help increase adoption of new therapies and diagnostic products and address unmet clinical needs in the region. Telemedicine and digital health platforms are being used to enable more specialists in the region to be available to their patients and facilitate follow-up visits for patients who have limited access to healthcare providers.
Lichen planus market trends in Japan reflects a maturing clinical research base and well-developed specialist care networks that support evaluation and adoption of innovative therapies. Evidence generation depends on the emphasis on evidenced-based clinical programs, which rely on the collaboration of academic and industrial partners to create them. Advanced diagnostic testing and the use of structured care pathways help physicians manage diseases. Payer and specialist clinic participation is important for determining access to medicines and other treatments.
Lichen planus market in South Korea demonstrates capacity building supported by specialist networks, academic research collaborations, and a receptive environment for technology adoption in dermatology. Focus on diagnostic refinement and multidisciplinary care pathways improves case identification and management consistency. Partnerships between local manufacturers and global companies enhance access to novel therapies and support clinical programs. Clinician education, professional society initiatives, and patient awareness efforts contribute to guideline alignment and practice standardization.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness and Diagnosis Rates
Advances In Therapeutic Options
High Cost of Specialized Treatments
Limited Access to Dermatology Services
Request Free Customization of this report to help us to meet your business objectives.
Competition in the global lichen planus market outlook centers on specialist biotechs and established dermatology firms racing to secure clinical-stage assets and differentiated mucosal delivery platforms for lichen planus, driven by licensing, partnerships and targeted acquisitions. Recently, T-Balance entered into a long-term agreement with CD4 Therapeutics that is effective until the year 2024; AFYX received clinical trial results for the Rivelin mucoadhesive patch; and both large and small biotech companies continue to develop JAK inhibitor (for lichen planus) clinical trial programs.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global lichen planus industry is being driven primarily by rising prevalence of autoimmune and inflammatory disorders and improved diagnostic awareness, while intensified clinical development and commercialization of targeted therapies further accelerates growth. High cost of specialized treatments constrains adoption and payer support, limiting reach in resource-constrained settings. North America remains in the dominating region due to advanced clinical infrastructure and strong research ecosystems, and Oral Lichen Planus is the dominating segment given its chronic mucosal burden and sustained therapeutic demand. Combined, these forces shape investment priorities, trial activity, and opportunities for novel topical and systemic options.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 200.1 Million |
| Market size value in 2033 | USD 393.38 Million |
| Growth Rate | 7.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Lichen Planus Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Lichen Planus Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Lichen Planus Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Lichen Planus Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Lichen Planus Market size was valued at USD 200.1 Million in 2024 and is poised to grow from USD 215.71 Million in 2025 to USD 393.38 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
Competition centers on specialist biotechs and established dermatology firms racing to secure clinical-stage assets and differentiated mucosal delivery platforms for lichen planus, driven by licensing, partnerships and targeted acquisitions. Recent strategic moves include T-Balance’s 2024 term sheet with CD4 Therapeutics, AFYX’s Rivelin mucoadhesive patch clinical readouts, and incumbents advancing JAK inhibitor programs into lichen planus trials. 'Novartis', 'Bristol-Myers Squibb', 'Amgen', 'Eli Lilly and Company', 'Pfizer', 'Sanofi', 'AbbVie', 'GSK', 'Merck & Co.', 'Johnson & Johnson', 'Regeneron Pharmaceuticals', 'Vertex Pharmaceuticals', 'Takeda Pharmaceutical Company', 'BioMarin Pharmaceutical', 'Astellas Pharma', 'Incyte Corporation', 'UCB', 'Mallinckrodt Pharmaceuticals', 'Sierra Oncology', 'Almirall'
Biologic Therapy Momentum: Interest in biologic and targeted therapies is reshaping R&D priorities for lichen planus, encouraging partnerships between specialty biotechs and academic centers to pursue mechanism-driven candidates. This trend supports a shift toward personalized treatment strategies, increased emphasis on durable responses and safety profiling, and development of companion diagnostics. Stakeholders including clinicians, payers, and patient groups are engaging earlier in development to align trial designs with real-world needs, creating pathways for differentiated product positioning and broader therapeutic options commercialization.
As per the global lichen planus market share, North America benefits from a combination of advanced clinical infrastructure, strong research ecosystems, and concentrated investments in dermatology that reinforce its leadership in the Lichen Planus market.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
